BelarusTuberculosis profile
Population  2014 9.5 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.73 (0.68–0.79) 7.7 (7.1–8.3)
Mortality (HIV+TB only) 0.08 (0.064–0.098) 0.84 (0.67–1)
Prevalence  (includes HIV+TB) 7.7 (3.8–13) 81 (40–136)
Incidence  (includes HIV+TB) 5.5 (4.7–6.4) 58 (50–67)
Incidence (HIV+TB only) 0.31 (0.26–0.37) 3.3 (2.8–3.8)
         
Case detection, all forms (%) 70 (60–81)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 34 (32–36) 69 (66–72)
MDR-TB cases among notified pulmonary
TB cases
990 (930–1 100) 720 (680–750)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 2 045   615
Pulmonary, clinically diagnosed 872   6
Extrapulmonary 310   10
       
Total new and relapse 3 858    
Previously treated, excluding relapses 416    
Total cases notified 4 274    
Among 3 858 new and relapse cases:
24 (<1%) cases aged under 15 years; male:female ratio: 2.7
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 1 990 (97%) 877 (84%) 2 867
Laboratory-confirmed RR-/MDR-TB cases     1 282
Patients started on MDR-TB treatment ***     1 903
TB/HIV 2014 Number (%)
TB patients with known HIV status 4 274 (100)
HIV-positive TB patients 271 (6)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 271 (100)
HIV-positive TB patients on antiretroviral therapy (ART) 191 (70)
HIV-positive people screened for TB 8 928  
HIV-positive people provided with IPT 539  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (87) 3 034
Previously treated cases, excluding relapse, registered in 2013 (71) 222
HIV-positive TB cases, all types, registered in 2013 (65) 138
RR-/MDR-TB cases started on second-line treatment in 2012 (54) 2 509
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 1.6
Culture (per 5 million population) 15.3
Drug susceptibility testing (per 5 million population) 4.2
Sites performing Xpert MTB/RIF 15
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2015  
National TB programme budget (US$ millions) 15
% Funded domestically 46%
% Funded internationally 23%
% Unfunded 31%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-09-01 Data: www.who.int/tb/data